Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Vanda Pharmaceutical (VNDA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 670,238
  • Shares Outstanding, K 43,950
  • Annual Sales, $ 146,020 K
  • Annual Income, $ -18,010 K
  • 36-Month Beta 1.49
  • Price/Sales 4.57
  • Price/Cash Flow 137.65
  • Price/Book 5.09

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.20 +15.53%
on 04/07/17
15.48 -1.49%
on 04/26/17
+1.00 (+7.02%)
since 03/28/17
3-Month
13.10 +16.41%
on 01/31/17
15.48 -1.49%
on 04/26/17
+1.45 (+10.51%)
since 01/27/17
52-Week
8.04 +89.68%
on 05/12/16
18.00 -15.28%
on 09/22/16
+6.09 (+66.48%)
since 04/28/16

Most Recent Stories

More News
Vanda Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 2, 2017

Conference Call and Webcast to Follow

VNDA : 15.25 (+0.33%)
Vanda and UCSF Announce License Agreement for CFTR Activators and Inhibitors

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today that it has entered into a license agreement with UC San Francisco (UCSF), under which Vanda will acquire an exclusive worldwide license...

VNDA : 15.25 (+0.33%)
How These Biotech Stocks are Faring? -- Corbus Pharma, Advaxis, Vanda Pharma, and Nivalis Therapeutics

On Monday, March 06, 2017, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Eight out of nine sectors ended Monday's trading session in bearish territories....

ADXS : 8.56 (-0.58%)
CRBP : 7.20 (+2.13%)
NVLS : 2.26 (+1.80%)
VNDA : 15.25 (+0.33%)
Vanda Pharmaceuticals Reports Fourth Quarter 2016 and Full Year 2016 Financial Results

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the fourth quarter and full year ended December 31, 2016.

VNDA : 15.25 (+0.33%)
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2016 Financial Results on February 15, 2017

Conference Call and Webcast to Follow

VNDA : 15.25 (+0.33%)
Merck KGaA Expands Distribution Deal with Roche (revised)

Germany-based Merck KGaA announced that it has expanded the distribution alliance with Roche Holding AG (RHHBY).

RHHBY : 32.6980 (-0.13%)
VNDA : 15.25 (+0.33%)
CBM : 59.35 (+1.28%)
Merck KGaA Expands Distribution Deal with Roche (revised)

Germany-based Merck KGaA announced that it has expanded the distribution alliance with Roche Holding AG (RHHBY).

RHHBY : 32.6980 (-0.13%)
VNDA : 15.25 (+0.33%)
CBM : 59.35 (+1.28%)
Research Reports Coverage on Biotech Stocks -- Cara Therapeutics, Heat Biologics, Vanda Pharma, and Opexa Therapeutics

For today, Stock-Callers.com takes a closer look at some Biotech equities: Cara Therapeutics Inc. (NASDAQ: CARA), Heat Biologics Inc. (NASDAQ: HTBX), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), and Opexa...

CARA : 15.89 (-0.44%)
HTBX : 0.79 (+2.60%)
VNDA : 15.25 (+0.33%)
OPXA : 0.68 (unch)
Abbott Labs to Close St. Jude Acquisition Later this Week

Abbott Laboratories (ABT) announced to close the acquisition of St. Jude Medical, Inc., (STJ) on Jan 4, 2017.

HSKA : 108.25 (+2.88%)
ABT : 43.64 (-0.02%)
STJ : 80.82 (+0.16%)
VNDA : 15.25 (+0.33%)
Immunomedics Completes Enrollment In Cancer Drug Study

Immunomedics (IMMU) achieved the planned enrollment in a phase II study on IMMU-132.

HSKA : 108.25 (+2.88%)
BAYRY : 124.4280 (+1.48%)
VNDA : 15.25 (+0.33%)
IMMU : 5.73 (+2.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics...

See More

Support & Resistance

2nd Resistance Point 15.45
1st Resistance Point 15.35
Last Price 15.25
1st Support Level 15.10
2nd Support Level 14.95

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.